Certified by Founder
Lodge
Indapta Therapeutics
start up
United States
- Seattle & Houston
- 18/12/2024
- Unknown
- $22,500,000
Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.
- Industry Biotechnology
- Website https://indapta.com/
- LinkedIn https://www.linkedin.com/company/indapta-therapuetics/
Derapi | $7,000,000 | (Feb 4, 2026)
AIRRIVED | $6,100,000 | (Feb 4, 2026)
enclaive | $4,849,418 | (Feb 4, 2026)
ecovia I bio | Undisclosed Amount | (Feb 4, 2026)
MaiaEdge | $20,000,000 | (Feb 4, 2026)
Mitra EV | $27,000,000 | (Feb 4, 2026)
Arbor(US) | $6,300,000 | (Feb 4, 2026)
Graici | $7,500,000 | (Feb 4, 2026)
Prenosis | $20,000,000 | (Feb 3, 2026)
Linq | $20,000,000 | (Feb 3, 2026)
Breezy | $10,000,000 | (Feb 3, 2026)
JJG Machining Group | $30,000,000 | (Feb 3, 2026)